Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 38 clinical trials
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in

  • 28 May, 2021
  • 1 location
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid

  • 23 Jul, 2021
  • 49 locations
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo) and talazoparib (also known as Talzenna) are when given as a combination treatment for

  • 15 May, 2021
  • 2 locations
Avelumab in Patients With MSS MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.

  • 12 Jun, 2021
  • 2 locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

  • 04 Aug, 2021
  • 503 locations
Open-Label Extension and Safety Study of Talazoparib

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

  • 07 Jul, 2021
  • 42 locations
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR

  • 04 Aug, 2021
  • 37 locations
Study of RP-3500 in Advanced Solid Tumors

The primary purpose of this study is to study the maximum tolerated dose (MTD) of orally-administered RP-3500 alone or in combination with talazoparib, a PARP inhibitor, in patients with

  • 19 May, 2021
  • 15 locations
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination

advanced breast cancer
measurable disease
  • 05 Feb, 2021
  • 3 locations
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination

  • 19 Jul, 2021
  • 2 locations